WANECAM 2 Symposium at the ASTMH 2025 Meeting
For those attending the ASTMH 2025 meeting, there will be an in-person WANECAM 2 Symposium titled “Towards the Novel Non-artemisinin Combinations for falciparum Malaria: Phase 3 Results, Capacity-Building in WANECAM 2 and Beyond“.
Date: November 13, 2025
Time: 11:30 AM U.S. / Canada Eastern Time
Location: ASTMH venue (Room 718A), Toronto, Canada
Abstract: In 2022, an estimated 249 million cases of malaria and 608,000 deaths occurred worldwide: 94% of predominantly P. falciparum malaria cases were recorded in the African Region. Artemisinin-based combination therapies (ACTs) are the current standard-of-care for P. falciparum malaria. Unfortunately, reports suggest that decades of continuous use of artemisinin and 4-aminoquinoline derivatives may have fostered the emergence of drug resistance in Plasmodium species in Southeast Asia and beyond, representing a major threat to artemisinin-based combination therapies (ACT) and intravenous artesunate. Already ubiquitous throughout the Greater Mekong Subregion of Southeast Asia, artemisinin partial resistance has emerged in several countries in East Africa and the Horn of Africa. If widespread artemisinin drug resistance were to occur, malaria pharmacotherapy would be severely impaired. Thus, there is an urgent need for new antimalarials with novel mechanisms of action that are effective against parasites harboring commonly occurring resistance mutations. Creative Format Description The symposium will open with an overview of the clinical trial capacity building within WANECAM2 as exemplified by the Niger trial site, followed by a presentation of the results of the KAMUMA phase 3 trial of a novel combination therapy, the ganaplacide (KAF156) -lumefantrine (LUM) – SDF (solid dispersion formulation). This will be followed by a report on the transmission-blocking methodology applied in that trial and its results. After that, a view into the future beyond WANECAM2 will be offered, elaborating on next-generation combinations and approaches for single-dose cure of malaria.
More information here.
